Engineering theranostic nanovehicles capable of targeting cerebrovascular amyloid deposits

Cerebral amyloid angiopathy (CAA) is characterized by the deposition of amyloid beta (Aβ) proteins within the walls of the cerebral vasculature with subsequent aggressive vascular inflammation leading to recurrent hemorrhagic strokes. The objective of the study was to develop theranostic nanovehicle...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	Journal of controlled release 2014-07, Vol.185, p.121-129
Hauptverfasser:	Agyare, Edward K., Jaruszewski, Kristen M., Curran, Geoffry L., Rosenberg, Jens T., Grant, Samuel C., Lowe, Val J., Ramakrishnan, Subramanian, Paravastu, Anant K., Poduslo, Joseph F., Kandimalla, Karunya K.
Format:	Artikel
Sprache:	eng
Schlagworte:	Alzheimer's disease Amyloid beta protein Amyloid beta-Peptides Animals Blood brain barrier Blood-Brain Barrier - metabolism Cell Line Cerebral Amyloid Angiopathy - diagnosis Cerebral Amyloid Angiopathy - therapy Cerebrovascular amyloid angiopathy Cerebrovascular inflammation Cyclophosphamide - administration & dosage Cyclophosphamide - therapeutic use Drug Delivery Systems Gadolinium - administration & dosage Humans Immunosuppressive Agents - administration & dosage Immunosuppressive Agents - therapeutic use Inflammation - diagnosis Inflammation - therapy Magnetic Resonance Imaging Mice Nanoparticles - metabolism Nanoparticles - therapeutic use Nanostructures - therapeutic use Plaque, Amyloid - pathology Theranostic nanoparticles Tomography, Emission-Computed, Single-Photon
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Schreiben Sie den ersten Kommentar!